Roche’s quantitative COVID-19 antibody test; Janssen buys a gene therapy asset; Zimmer Acquires A&E Medical; Glaucoma research study: Merck chooses TriNKET cancer immunotherapy program; Ovid fails Angelman phase 3 study
Delveinsight
DECEMBER 3, 2020
The company anticipates the test can aid in tracking the success of vaccines and recognize people who have recovered from infection and could serve as convalescent plasma donors or help in the development of new therapies. Merck chooses TriNKET cancer immunotherapy program. Bayer creates cell and gene therapy platform.
Let's personalize your content